Enhanced CAR T-Cell Therapy Shows Promise in B-Cell Cancers
A phase I clinical trial at The Ohio State University has demonstrated that an enhanced CAR T-cell therapy can effectively treat relapsed or treatment-resistant B-cell cancers. By incorporating the OX40 protein and a rapid manufacturing process, researchers achieved positive clinical outcomes with minimal side effects.
Why it matters
This represents a significant advancement in personalized cancer immunotherapy, offering new hope for patients who have exhausted standard treatment options.
Results from a phase I clinical trial led by The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) show a possible way to improve therapy options for patients with relapsed or treatment-resistant B-cell blood cancers.
The findings were published in Blood Cancer Discovery .
Researchers were able to build on earlier work done at Ohio State that used CAR T-cell therapy to enhance treatment of B-cell blood cancers. About half of all blood cancers are B-cell blood cancers, including lymphoma and some leukemias.
This trial tested CAR T-cell therapy targeting three proteins - CD19, CD20 and CD22 - and used a different protein called OX40 to boost immune response in patients.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in